Figure 3

In vivo competition of [⁶⁸Ga]Ga-DO3A-S01-GCG in NHP. Maximum Intensity Projections (MIPs, summed 0–90 minutes) of all PET examinations in the study, ranked after ascending DO3A-S01-GCG peptide mass dose. (A) SUV quantification of the dynamic uptake for all PET examinations in the liver (B) and spleen (C). SUV_90min as endpoint for liver binding of [⁶⁸Ga]Ga-DO3A-S01-GCG was inversely proportional to the increase in co-injected DO3A-S01-GCG peptide mass dose. (D) There was a clear difference in liver binding, assessed as SUV_90min, between the groups with the lowest (<0.2 µg/kg) and highest (≥5 µg/kg) administered peptide mass doses. ****Indicate p < 0.001.